相关实验视频

Updated: Jun 24, 2025

Evaluating In Vitro DNA Damage Using Comet Assay

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

在前列腺癌中使用PARP抑制剂,现在是组合的时候了吗?

Diego Teyssonneau¹, Charles Dariane², Eric Barret³

¹Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, Bordeaux 33000, France.

Therapeutic advances in medical oncology

|June 3, 2024

概括

转移性前列腺癌是致命的,但多ADP-ribose聚合酶 (PARP) 抑制剂显示出有前途. 本综述探讨了单独使用PARP抑制剂或与新激素疗法一起使用的PARP抑制剂,考虑了它们的有效性,而不考虑同源复合修复 (HRR) 缺乏.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

转移性前列腺癌仍然是癌症相关死亡的重要原因.
同源复合修复 (HRR) 途径的改变与侵袭性疾病有关.
像olaparib和rucaparib这样的PARP抑制剂 (PARPi) 已被批准用于HRR缺乏的转移性割耐性前列腺癌 (mCRPC),特别是具有BRCA2变异的前列腺癌.

研究的目的:

审查PARPi作为前列腺癌单一治疗的优缺点.
讨论将PARPi与新激素疗法 (NHT) 结合在一起的潜在协同效应.
为了评估分子选择对PARPi治疗的必要性,独立于HRR缺乏.

主要方法:

关于PARP抑制剂和前列腺癌新激素疗法现有研究的文献综述.
对临床试验数据和关于PARPi疗效的研究结果的分析.
探索关于PARPi和NHTs联合使用的新兴假设.

主要成果:

PARPi在mCRPC患者中显示出抗瘤作用,这些患者具有HRR基因变异.
新出现的证据表明,PARPi和NHT之间可能存在协同作用.
PARPi的疗效可能超出HRR缺乏症患者的范围.

结论:

PARPi代表了转移性前列腺癌的宝贵治疗选择,特别是在HRR改变的病例中.
将PARPi与NHT结合起来可能会提供更高的疗效,可能独立于HRR状态.
需要进一步的研究来确定最佳的治疗策略和对基于PARPi的治疗方法的患者选择标准.

关键词:

修复DNA的修复DNA的修复在 PARP 抑制剂的使用中.同类的重组修复复合.转移性前列腺癌前列腺癌

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...